Novo Nordisk disclosed several key updates from its cardiometabolic and hematology pipelines Wednesday as the drugmaker ...

It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field's next frontier: staving off the losses ...

Aca­dia Phar­ma­ceu­ti­cals has sold its pri­or­i­ty re­view vouch­er for $150 mil­lion, the com­pa­ny said Tues­day, but did not dis­close the buy­er … ...

Catalent reported a slight revenue upswing during its latest quarterly results, which CEO Alessandro Maselli attributed to ...

Response Pharmaceuticals believes its experimental drug can lessen the persistent weight gain associated with antipsychotics.

Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study. The ...

Zealand is po­si­tion­ing the drug as a po­ten­tial stand­alone re­place­ment for GLP-1s or as the first med­i­cine that ...

Johnson & Johnson’s CD38 inhibitor Darzalex showed a benefit in delaying or preventing disease progression in patients with ...

Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...

Gilead and Ar­cel­lx’s ear­ly tri­al da­ta on their mul­ti­ple myelo­ma cell ther­a­py show that pa­tients saw no cas­es of ...

Troubled mental health startup Cerebral has agreed to pay nearly $3.7 million in connection with its efforts to encourage unauthorized prescriptions of ADHD medications and other ...

Vertex said it made $2 million in revenue from the first patient who received its sickle cell therapy Casgevy. The commercial launches of Casgevy and bluebird bio’s Lyfgenia have been ...